undamentalytics Newsletter

Lombardi Ronald M.: insider trades

Chief executive, Chief financial officer, Director at 2 companies we cover. 4 open-market purchases and 14 sales not made under a pre-set plan, reported from August 22, 2011 to November 21, 2024.

Would copying Lombardi Ronald M.’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 4 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on August 23, 2011 into $11,124 by November 2, 2026, +0.7% a year. The copy held shares only 26% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $19,418, +4.5% a year (the S&P 500 held throughout made $84,798, +15.1% a year). Beta against the index was 0.35. Twelve months after each report, the average purchase was −8.2% against the S&P 500 (median −20.2%), and 25% beat it. Measured from the trade date, the insider’s own timing, the average was +3.5%. After their sales, the shares moved −10.5% against the index over 12 months on average (a negative figure means selling was the right call); 79% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$25.0k$50.0k$75.0k 20112013201520172019202120232025 $84.8k$19.4k$11.1k
Copying Lombardi Ronald M.S&P 500, same days investedS&P 500, held throughout $10,000 copying Lombardi Ronald M.’s open-market purchases from August 23, 2011, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+0.7%
S&P 500, same days invested
+4.5% (held throughout +15.1%)
Time in shares
26%
Sharpe ratio (S&P 500)
0.06 (0.82)
Biggest drop (S&P 500)
−60% (−34%)
Market sensitivity (beta)
0.35
Purchases copied
4

Trade by trade

Lombardi Ronald M.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 4 −12.0% −12.7% 25% 4 −2.29 0.11 No reliable evidence
Purchases, 6 months after the report 4 +7.1% +1.8% 50% 4 0.51 0.64 No reliable evidence
Purchases, 12 months after the report 4 −8.2% −20.2% 25% 4 −0.55 0.62 No reliable evidence
Purchases, 12 months after the trade 4 +3.5% −10.6% 50% 4 0.16 0.88 No reliable evidence
Sales, 3 months after the report 14 −3.2% −2.6% 57% 8 −0.71 0.50 No reliable evidence
Sales, 12 months after the report 14 −10.5% −16.6% 79% 8 −0.35 0.74 No reliable evidence
Sales, 12 months after the trade 14 −11.0% −15.8% 79% 8 −0.43 0.68 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Prestige Consumer Healthcare Inc. PBH Chief Executive Officer214August 22, 2011November 21, 2024
Acco Brands Corp ACCO —20November 16, 2020February 18, 2022

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
November 21, 2024November 19, 2024 PBH Sale $898,241 +0.1%−45.3%−40.9%
November 19, 2024November 18, 2024 PBH Sale $6,789,764 +4.7%−45.1%−39.7%
August 9, 2023August 8, 2023 PBH Sale $2,150,536 −6.4%−19.6%−15.9%
November 21, 2022November 18, 2022 PBH Sale $2,292,666 +0.4%−19.9%−19.0%
February 18, 2022February 17, 2022 ACCO Purchase $531,000 −9.7%−26.4%−27.9%
November 15, 2021November 12, 2021 PBH Sale $3,287,600 +1.4%+9.6%+7.8%
November 16, 2020November 13, 2020 ACCO Purchase $341,500 +1.1%−14.0%+4.4%
May 13, 2020May 12, 2020 PBH Sale $1,183,720 −23.0%−25.5%−26.0%
February 6, 2018February 5, 2018 PBH Purchase $251,580 −23.9%−28.4%−25.6%
February 12, 2015February 10, 2015 PBH Sale $871,136 +8.4%+32.6%+31.2%
September 17, 2014September 15, 2014 PBH Sale $19,938 +3.0%+50.4%+42.6%
August 23, 2013August 21, 2013 PBH Sale $455,630 −6.2%−17.3%−15.8%
August 22, 2013August 20, 2013 PBH Sale $549,591 −3.1%−17.8%−13.5%
August 20, 2013August 16, 2013 PBH Sale $312,236 −5.4%−15.8%−9.2%
August 16, 2013August 14, 2013 PBH Sale $762,752 −2.4%−8.8%−9.4%
August 8, 2013August 6, 2013 PBH Sale $860,687 −2.8%−8.7%−23.3%
August 6, 2013August 5, 2013 PBH Sale $107,116 −13.2%−15.1%−23.5%
August 22, 2011August 18, 2011 PBH Purchase $87,400 −15.6%+35.9%+62.9%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Lombardi Ronald M. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.